PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Войти

Зарегистрироваться
Забыли пароль?

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

IMG-20170730-WA0004
20170731 192225
DJI 0032
20180130 153036
20180131 184153
IMG-20170806-WA0015
  • Patient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data - 09/18/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-17 By FDA
  • Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 29, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Date of authorisation: 02/06/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Date of authorisation: 16/01/2020, Revision: 7, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Hydrocortisone Aguettant, Status: Application withdrawn
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Summary of opinion: Paxlovid, 16/10/2025 Positive
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Wayrilz, rilzabrutinib, Status: Opinion
    Source: EMA - New medicines: human Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Brinsupri, Brensocatib, Status: Opinion
    Source: EMA - New medicines: human Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Rezurock, Belumosudil, Status: Opinion
    Source: EMA - New medicines: human Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Austedo, deutetrabenazine, Status: Opinion
    Source: EMA - New medicines: human Published on 2025-10-17
  • Human medicines European public assessment report (EPAR): Arava, leflunomide, Date of authorisation: 02/09/1999, Revision: 43, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-17
Предыдущие записи
Тема: Scaffold от Danny Cooper.